国内第5款生物类似药申报上市!该乳腺癌药物市场迎竞争新局

制药网
Nov 12

11月11日,国家药品监督管理局药品审评中心(CDE)网站的一则受理信息,为国内HER2阳性乳腺癌治疗领域注入新活力——石药集团递交的帕妥珠单抗注射液上市申请正式获受理。作为靶向HER2通路的关键药物,帕妥珠单抗的生物类似药研发赛道已呈现多点开花的格局,而石药集团的入局,无疑将推动该领域的竞争进入新阶段。乳腺癌严重危害女性健康,其中HER2阳性亚型约占全部病例的20%-30%。这类患者肿瘤细胞表面...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10